Display options
Cite
Peerschke EI, Brandwijk RJ, Dembitzer FR, et al. Soluble gC1qR in Blood and Body Fluids: Examination in a Pancreatic Cancer Patient Cohort. Int J Cancer Res Mol Mech. 2015;1(3)doi: 10.16966/ijcrmm.110.
Peerschke, E. I., Brandwijk, R. J., Dembitzer, F. R., Kinoshita, Y., & Ghebrehiwet, B. (2015). Soluble gC1qR in Blood and Body Fluids: Examination in a Pancreatic Cancer Patient Cohort. International journal of cancer research and molecular mechanisms, 1(3), . https://doi.org/10.16966/ijcrmm.110
Peerschke, Ellinor Ib, et al. "Soluble gC1qR in Blood and Body Fluids: Examination in a Pancreatic Cancer Patient Cohort." International journal of cancer research and molecular mechanisms vol. 1,3 (2015). doi: https://doi.org/10.16966/ijcrmm.110
Peerschke EI, Brandwijk RJ, Dembitzer FR, Kinoshita Y, Ghebrehiwet B. Soluble gC1qR in Blood and Body Fluids: Examination in a Pancreatic Cancer Patient Cohort. Int J Cancer Res Mol Mech. 2015 Oct;1(3). doi: 10.16966/ijcrmm.110. Epub 2015 Sep 03. PMID: 26973884; PMCID: PMC4786181.
Copy Download .nbib Format: NLM
Share it on

Int J Cancer Res Mol Mech. 2015 Oct;1(3). doi: 10.16966/ijcrmm.110. Epub 2015 Sep 03.

Soluble gC1qR in Blood and Body Fluids: Examination in a Pancreatic Cancer Patient Cohort.

International journal of cancer research and molecular mechanisms

Ellinor Ib Peerschke, Ricardo Jmge Brandwijk, Francine R Dembitzer, Yayoi Kinoshita, Berhane Ghebrehiwet

Affiliations

  1. Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center and Department of Laboratory Medicine and Pathology, Weill Cornell Medical Center, NY, NY, USA.
  2. Hycult Biotech, R&D Department, Uden, The Netherlands.
  3. Department of Pathology, Mount Sinai School of Medicine, NY, NY, USA.
  4. Department of Medicine, Stony Brook University, Stony Brook NY, USA.

PMID: 26973884 PMCID: PMC4786181 DOI: 10.16966/ijcrmm.110

Abstract

BACKGROUND: gC1qR is a multifunctional cellular protein that has been linked to inflammation and cancer. gC1qR is highly upregulated in adenocarcinomas as compared to normal tissue counterparts, and soluble gC1qR (sgC1qR) has been detected

AIM: The present study explored the tissue expression of gC1qR in pancreatic cancer by immunohistochemistry, and the presence of sgC1qR

METHODS: Tissue expression of gC1qR by pancreatic adenocarcinoma was visualized by immunohistochemistry. SgC1qR was quantified in serum from healthy volunteers (n=20) and pancreatic cancer patients (n=34), as well as in malignant pleural (n=23) and peritoneal effusions (n=27), using a newly developed, sensitive immunocapture sandwich ELISA.

RESULTS: Overexpression of gC1qR was confirmed in pancreatic adenocarcinoma compared to nonmalignant pancreatic tissue. Moreover, increased serum levels of sgC1qR (0.29 ± 0.22 ng/ml) were noted in patients with metastatic pancreatic cancer compared to healthy controls (0.15 ± 0.10 ng/ml) (mean ± S.D.) (p=0.035). In 11 of 16 patients for whom sequential samples were available, serum sgC1qR levels rose with disease progression, and paralleled changes in tumor biomarkers, CEA and CA19.9. In addition to blood, sgC1qR was detected in malignant pleural (0.55 ± 0.47 ng/ml) and peritoneal effusions (0.57 ± 0.38 ng/ml).

CONCLUSION: This study provides the first evidence for the presence of sgC1qR

Keywords: Blood; Complement; ELISA; Pancreatic cancer; Peritoneal fluid; gC1qR

References

  1. Immunobiology. 1998 Aug;199(2):225-38 - PubMed
  2. Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8552-7 - PubMed
  3. Mol Cell Biol. 2010 Mar;30(6):1303-18 - PubMed
  4. Clin Immunol Immunopathol. 1997 Jul;84(1):17-26 - PubMed
  5. J Immunol. 2002 Mar 1;168(5):2441-8 - PubMed
  6. Mol Cell Biochem. 2004 Dec;267(1-2):133-9 - PubMed
  7. J Immunol. 1998 Apr 1;160(7):3534-42 - PubMed
  8. Clin Immunol. 1999 Sep;92(3):246-55 - PubMed
  9. Int J Cancer. 2004 Jul 10;110(5):741-50 - PubMed
  10. Immunol Rev. 2001 Apr;180:65-77 - PubMed
  11. J Biol Chem. 2011 Jul 1;286(26):23093-101 - PubMed
  12. FEBS Lett. 1997 Nov 24;418(1-2):111-4 - PubMed
  13. Immunobiology. 2007;212(4-5):333-42 - PubMed
  14. Histochem Cell Biol. 2000 Sep;114(3):245-55 - PubMed
  15. J Biol Chem. 1996 Oct 25;271(43):26739-44 - PubMed
  16. J Clin Invest. 2000 Nov;106(10):1239-49 - PubMed
  17. J Biol Chem. 1996 May 31;271(22):13040-7 - PubMed
  18. EMBO J. 2000 Apr 3;19(7):1458-66 - PubMed
  19. J Histochem Cytochem. 2012 Jun;60(6):467-74 - PubMed
  20. J Biol Chem. 2011 Feb 18;286(7):5197-203 - PubMed
  21. Exp Mol Pathol. 2013 Feb;94(1):210-5 - PubMed
  22. J Exp Med. 1994 Jun 1;179(6):1809-21 - PubMed
  23. Adv Exp Med Biol. 2006;586:95-105 - PubMed
  24. Blood. 2001 Apr 15;97(8):2342-50 - PubMed
  25. Cell Signal. 2011 Oct;23 (10 ):1563-77 - PubMed
  26. J Lab Clin Med. 1999 Jun;133(6):541-50 - PubMed
  27. Blood. 2002 May 15;99(10):3585-96 - PubMed
  28. FASEB J. 2001 Jun;15(8):1487-9 - PubMed
  29. Cancer Res. 2008 Sep 1;68(17):7210-8 - PubMed
  30. J Surg Oncol. 2009 Oct 1;100(5):382-6 - PubMed
  31. J Immunol. 2014 Jan 1;192(1):377-84 - PubMed
  32. Mol Immunol. 2014 Oct;61(2):100-9 - PubMed
  33. Biochem Biophys Res Commun. 2002 Mar 8;291(4):829-37 - PubMed
  34. J Biol Chem. 1997 Sep 26;272(39):24363-70 - PubMed
  35. J Gen Virol. 1998 Jul;79 ( Pt 7):1677-85 - PubMed

Publication Types

Grant support